Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Latha G, Nair"'
Autor:
Prasanthi Geda, Mark A. McCoy, Liping Yang, Chaomin Li, Armetta D. Hill, Xavier Fradera, Marianne L. Spatz, Matthew Ernst Voss, Carolyn Michele Cammarano, Pierre Daublain, Xiao Wang, Christopher F. Thompson, B. Wesley Trotter, C. Gary Marshall, Michael H. Reutershan, Peter Goldenblatt, Latha G. Nair, Manami Shizuka, Tammie C. Yeh, John G. Cryan, Isabelle Dussault, Michelle Martinez, Mingmei Cai, Raymond A. Kemper, Binyuan Sun, Michelle R. Machacek, Dietrich Steinhuebel, Giovanna Scapin, Michael D. Altman, Stephane L. Bogen, Matthew Christopher, Dapeng Chen, Victoria Kutilek, Weidong Pan
Publikováno v:
Journal of Medicinal Chemistry. 64:16213-16241
Identification of low-dose, low-molecular-weight, drug-like inhibitors of protein-protein interactions (PPIs) is a challenging area of research. Despite the challenges, the therapeutic potential of PPI inhibition has driven significant efforts toward
Autor:
Yuan, Tian, Brian R, Lahue, Yao, Ma, Latha G, Nair, Weidong, Pan, Ronald J, Doll, Timothy, Guzi, Yaolin, Wang, Stéphane L, Bogen
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 61:128625
The discovery of potent, bioavailable small molecule inhibitors of p53-HDM2 PPI led us to investigate subsequent modifications to address a CYP3A4 time-dependent inhibition liability. On the basis of the crystal structure of HDM2 in complex with 2, f
Autor:
Yaolin Wang, Yao Ma, Philip Lipari, Stephane L. Bogen, Cynthia Seidel-Dugan, Yinghui Lin, Asra Mirza, Craig R. Gibeau, Doll Ronald J, Corey Strickland, Giovanna Scapin, Winifred W. Prosise, Diane Rindgen, Paul Reichert, Xiaoying Wang, Ming Liu, Brian R. Lahue, Daniel J. Hicklin, Gerald W. Shipps, Tian Yuan, Elise Seigel, Suxing Liu, W. Robert Bishop, Weidong Pan, Amin A. Nomeir, Latha G. Nair
Publikováno v:
ACS Medicinal Chemistry Letters. 7:324-329
A new subseries of substituted piperidines as p53-HDM2 inhibitors exemplified by 21 has been developed from the initial lead 1. Research focused on optimization of a crucial HDM2 Trp23-ligand interaction led to the identification of 2-(trifluoromethy
Autor:
Gerald W. Shipps, Doll Ronald J, Yao Ma, Latha G. Nair, Stephane L. Bogen, Brian R. Lahue, Weidong Pan, Yaolin Wang
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 24:1983-1986
The discovery of 3,3-disubstituted piperidine 1 as novel p53–HDM2 inhibitors prompted us to implement subsequent SAR follow up directed towards piperidine core modifications. Conformational restrictions and further functionalization of the piperidi
Autor:
Manami Shizuka, Margarita Kirova-Snover, Yao Ma, Yaolin Wang, Weidong Pan, Mark A. Miccoy, Brian R. Lahue, Matthew E. Voss, Stephane L. Bogen, Timothy J. Guzi, Latha G. Nair, Yuan Liu, Graig R. Gibeau, Gerald W. Shipps, Tian Yuan, W. Brent Clayton
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 24:1026-1030
The present invention provides a compound of Formula I (The formula should be inserted here) as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also
Autor:
Jun Wang, Weidong Pan, F. George Njoroge, Vinay Girijavallabhan, Ying Huang, Ping Chen, Latha G. Nair, Frank Bennett, Angela Kerekes, Ashok Arasappan, Qun Dang, Qingmei Hong, Stephane L. Bogen, Zhidan Liu, Quang Truong, Sara Esposite, Yuhua Huang, Bancha Vibulbhan, Haiyan Pu, Andrew Stamford, Dmitri A. Pissarnitski, Kevin X. Chen, David B. Olsen, Vishal Verma, David Cole, Zhiqiang Zhao, Randall R. Rossman, Alvarez Carmen S
Publikováno v:
Nucleosides, nucleotidesnucleic acids. 35(6)
Novel 2'-modified guanosine nucleosides were synthesized from inexpensive starting materials in 7-10 steps via hydroazidation or hydrocyanation reactions of the corresponding 2'-olefin. The antiviral effectiveness of the guanosine nucleosides was eva
Autor:
Weing Yang, Bancha Vibulbhan, Neng-Yang Shih, Yuhua Huang, Latha G. Nair, Doll Ronald J, Kevin X. Chen, Stephane L. Bogen, F. George Njoroge, Frank Bennett
Publikováno v:
Tetrahedron Letters. 51:3057-3061
The Hepatitis C Virus (HCV) is a major health hazard and its infection is a leading cause of chronic liver disease world wide. In our efforts toward the discovery of a back up to our first clinical candidate, Boceprevir (SCH 503034), we approached th
Autor:
Hendrata Siska, Frank Bennett, Xiao Tong, Francisco Velazquez, Regina Huelgas, Kuo-Chi Cheng, Srikanth Venkatraman, Yuhua Huang, Andrew T. McPhail, Melissa Blackman, Patrick Pinto, Mousumi Sannigrahi, F. George Njoroge, Stephane L. Bogen, Raymond G. Lovey, Latha G. Nair, Ashok Arasappan
Publikováno v:
Journal of Medicinal Chemistry. 53:3075-3085
HCV infection affects more than 170 million people worldwide and many of those patients will reach the end stage complications of the disease which include hepatocarcinoma and liver failure. The success rate for treatment of patients infected with ge
Publikováno v:
Tetrahedron Letters. 51:1276-1279
An efficient route for the synthesis of sterically hindered substituted and unsubstituted 2,6-dioxo tetrahydropyrimidines from amine 1 is described. These analogs are active against HCV NS3 serine protease. The biological data for some of the represe
Autor:
Rong Liu, Kuo-Chi Cheng, Kevin X. Chen, Ashok Arasappan, Xiao Tong, Frank Bennett, Edwin Jao, Srikanth Venkatraman, Bancha Vibulbhan, Anil K. Saksena, Stephane L. Bogen, Sumei Ruan, Weidong Pan, Latha G. Nair, Viyyoor M. Girijavallabhan, F. George Njoroge, Zhuyan Guo
Publikováno v:
Journal of Medicinal Chemistry. 52:3679-3688
Hepatitis C is the most prevalent liver disease. Viral hepatitis C (HCV), a small (+)-RNA virus, infects chronically an estimated 300 million people worldwide. Results of Phase I clinical studies with our first generation HCV inhibitor Boceprevir, SC